(Q37878771)

24 August 2017

1 reference

title

Novel proteasome inhibitors to overcome bortezomib resistance (English)

1 reference

24 August 2017

3

Lewis E Kay

1 reference

24 August 2017

Aaron D Schimmer

4

0 references

author name string

Amy M Ruschak

series ordinal

1

1 reference

PubMed ID

21606441

24 August 2017

Malik Slassi

series ordinal

2

1 reference

PubMed ID

21606441

24 August 2017

language of work or name

English

0 references

publication date

23 May 2011

1 reference

Journal of the National Cancer Institute

24 August 2017

1 reference

24 August 2017

103

1 reference

24 August 2017

1007-1017

1 reference

24 August 2017

13

1 reference

The structure of the APPBP1-UBA3-NEDD8-ATP complex reveals the basis for selective ubiquitin-like protein activation by an E1

24 August 2017

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

Insights into the ubiquitin transfer cascade from the structure of the activating enzyme for NEDD8

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

Structures of the SUMO E1 provide mechanistic insights into SUMO activation and E2 recruitment to E1

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

A multiubiquitin chain is confined to specific lysine in a targeted short-lived protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

Dual E1 activation systems for ubiquitin differentially regulate E2 enzyme charging

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

Genome analysis and functional characterization of the E2 and RING-type E3 ligase ubiquitination enzymes of Arabidopsis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

A function for monoubiquitination in the internalization of a G protein-coupled receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

A single motif responsible for ubiquitin recognition and monoubiquitination in endocytic proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

Histone H2A monoubiquitination represses transcription by inhibiting RNA polymerase II transcriptional elongation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

The deubiquitinating enzyme USP1 regulates the Fanconi anemia pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

Regulation of DNA repair by ubiquitylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

Regulation of monoubiquitinated PCNA by DUB autocleavage

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

Structure and functions of the 20S and 26S proteasomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

The proteasome: paradigm of a self-compartmentalizing protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

A subcomplex of the proteasome regulatory particle required for ubiquitin-conjugate degradation and related to the COP9-signalosome and eIF3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

Structure of 20S proteasome from yeast at 2.4 A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

A gated channel into the proteasome core particle

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

Assembly, structure, and function of the 26S proteasome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

The structure of the mammalian 20S proteasome at 2.75 A resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

The active sites of the eukaryotic 20 S proteasome and their involvement in subunit precursor processing

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

Autocatalytic subunit processing couples active site formation in the 20S proteasome to completion of assembly

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

Conformational constraints for protein self-cleavage in the proteasome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

Cleavage motifs of the yeast 20S proteasome beta subunits deduced from digests of enolase 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

Contribution of proteasomal beta-subunits to the cleavage of peptide substrates analyzed with yeast mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

Identification of the yeast 20S proteasome catalytic centers and subunit interactions required for active-site formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

21 January 2018

Proteasome activators

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

Interactions of PAN's C-termini with archaeal 20S proteasome and implications for the eukaryotic proteasome–ATPase interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

The catalytic sites of 20S proteasomes and their role in subunit maturation: a mutational and crystallographic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

A protein catalytic framework with an N-terminal nucleophile is capable of self-activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

Homology of proteasome subunits to a major histocompatibility complex-linked LMP gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

Sensitivity of tumor cells to proteasome inhibitors is associated with expression levels and composition of proteasome subunits

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

Carfilzomib can induce tumor cell death through selective inhibition of the chymotrypsin-like activity of the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

Ubiquitin-proteasome system stress sensitizes ovarian cancer to proteasome inhibitor-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

Crystal structures of Salinosporamide A (NPI-0052) and B (NPI-0047) in complex with the 20S proteasome reveal important consequences of beta-lactone ring opening and a mechanism for irreversible binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

20S proteasome and its inhibitors: crystallographic knowledge for drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

The development of proteasome inhibitors as anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

Phase I study of bortezomib in refractory or relapsed acute leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma/leukemia cells derived from the Jurkat cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

Effect of noncompetitive proteasome inhibition on bortezomib resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

No evidence of mutations of the PSMB5 (beta-5 subunit of proteasome) in a case of myeloma with clinical resistance to Bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

Characterization of bortezomib-adapted I-45 mesothelioma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

The proteasome inhibitor CEP-18770 enhances the anti-myeloma activity of bortezomib and melphalan

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

A phase 1 dose escalation study of the safety and pharmacokinetics of the novel proteasome inhibitor carfilzomib (PR-171) in patients with hematologic malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

Salinosporamide A: a highly cytotoxic proteasome inhibitor from a novel microbial source, a marine bacterium of the new genus salinospora.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

Pharmacodynamic and efficacy studies of the novel proteasome inhibitor NPI-0052 (marizomib) in a human plasmacytoma xenograft murine model

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

NPI-0052, a novel proteasome inhibitor, induces caspase-8 and ROS-dependent apoptosis alone and in combination with HDAC inhibitors in leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

Structure of the gene for porcine peptide antibiotic PR-39, a cathelin gene family member: comparative mapping of the locus for the human peptide antibiotic FALL-39

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

Proline- and arginine-rich peptides constitute a novel class of allosteric inhibitors of proteasome activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

TROSY-based NMR evidence for a novel class of 20S proteasome inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

Prophylactic value of clioquinol against travellers' diarrhoea.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

Trial of clioquinol in cholera.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

Relation between subacute myelo-optic neuropathy (S.M.O.N.) and clioquinol: nationwide survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

Clinical analysis of longstanding subacute myelo-optico-neuropathy: sequelae of clioquinol at 32 years after its ban.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

Clioquinol inhibits the proteasome and displays preclinical activity in leukemia and myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

Clioquinol, a therapeutic agent for Alzheimer's disease, has proteasome-inhibitory, androgen receptor-suppressing, apoptosis-inducing, and antitumor activities in human prostate cancer cells and xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

Metal ionophores - an emerging class of anticancer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

Use of the copper/zinc ratio in the diagnosis of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

Quantitative analysis of copper, zinc and copper/zinc ratio in selected human brain tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

The ubiquitin-activating enzyme E1 as a therapeutic target for the treatment of leukemia and multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJR160

21 January 2018

Identifiers

DOI

10.1093/JNCI/DJR160

1 reference

24 August 2017

1 reference

PubMed ID

21606441